Clinical outcomes after reversal of dabigatran in daily practice: real-world use of idarucizumab 2015–2019
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3366
Abstract: Idarucizumab was introduced in Europe in December 2015 as an antidote to dabigatran. Whether reversing the anticoagulant effect of dabigatran actually reduces the risk of bleeding complications and mortality remains sparsely described. No randomized placebo-controlled… read more here.
Keywords: world use; real world; use idarucizumab; idarucizumab ... See more keywords
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s140377
Abstract: Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that… read more here.
Keywords: use; use idarucizumab; idarucizumab reversing; reversing dabigatran ... See more keywords